# Crossignal Therapeutics

Source: https://onco.cc/companies/crossignal-therapeutics/  
OnCo record `crossignal-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Crossignal Therapeutics develops small-molecule medicines meant to stop tumours hiding from the immune system. Its lead drug, CT3001, is in an early trial in advanced bowel, pancreatic and other solid cancers.

## Summary

Crossignal Therapeutics, Inc., of La Jolla, California, develops small-molecule anti-cancer immunotherapies, using an assay platform it calls PPS to screen against difficult G-protein-coupled receptor targets. Its lead, CT3001, is described as a first-in-class small-molecule inhibitor of GPR35; company news links it to IDO1-mediated tumour immune escape through the Hippo-YAP pathway. CT3001 received FDA IND clearance in December 2023 and the company announced first-in-patient dosing in October 2024 in a phase 1/2 study (NCT06598007) of CT3001 alone and with FOLFOX, with a phase 2a part planned in advanced colorectal or pancreatic cancer. A second programme, CT3021, is a small-molecule antagonist of adenosine A2a, A2b and A1 receptors. Its first registered cancer trial, NCT06598007, was posted on ClinicalTrials.gov in September 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: La Jolla, CA
- Type: biotech
- Website: https://crossignaltherapeutics.com/

## Notes

-  No OnCo technology record matches a small-molecule GPR35 inhibitor, so none is linked; CT3001 is not an antibody against PD-1, PD-L1 or CTLA-4.
- Founding year and financing not stated on the company website.
- Company website, news and clinical trial pages read on 29 October 2026.

## Sources

- Official website: https://crossignaltherapeutics.com/
- CT3001 clinical trial page: https://crossignaltherapeutics.com/clinical-trial

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- trials: [A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06598007/)

---
JSON: https://onco.cc/api/v1/entities/crossignal-therapeutics.json